Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH.

Cell. 2012 Feb 3;148(3):421-33. doi: 10.1016/j.cell.2012.01.017.

2.
3.

PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.

Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, Maurice DH, Backx PH.

Circ Res. 2007 Aug 17;101(4):400-8. Epub 2007 Jul 5.

4.

Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans.

Adderley SP, Dufaux EA, Sridharan M, Bowles EA, Hanson MS, Stephenson AH, Ellsworth ML, Sprague RS.

Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1617-24. doi: 10.1152/ajpheart.01226.2008. Epub 2009 Feb 27.

5.

Resveratrol as a calorie restriction mimetic: therapeutic implications.

Chung JH, Manganiello V, Dyck JR.

Trends Cell Biol. 2012 Oct;22(10):546-54. doi: 10.1016/j.tcb.2012.07.004. Epub 2012 Aug 10. Review.

6.

Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.

Kapui Z, Bence J, Boronkay E, Mikus E, Urbán Szabó K, Baranyi A, Arányi P.

Neurobiology (Bp). 1999;7(1):71-3. No abstract available.

PMID:
10746252
7.

Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK.

Park SJ, Ahmad F, Um JH, Brown AL, Xu X, Kang H, Ke H, Feng X, Ryall J, Philp A, Schenk S, Kim MK, Sartorelli V, Chung JH.

EBioMedicine. 2017 Apr;18:128-138. doi: 10.1016/j.ebiom.2017.03.019. Epub 2017 Mar 14.

8.

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol.

Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH.

Diabetes. 2010 Mar;59(3):554-63. doi: 10.2337/db09-0482. Epub 2009 Nov 23.

9.

Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells.

Naro F, Sette C, Vicini E, De Arcangelis V, Grange M, Conti M, Lagarde M, Molinaro M, Adamo S, Némoz G.

Mol Biol Cell. 1999 Dec;10(12):4355-67.

10.
11.

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.

Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA.

Cell Metab. 2012 May 2;15(5):675-90. doi: 10.1016/j.cmet.2012.04.003.

12.

Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.

Liu S, Laliberté F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, Huang Z.

Biochemistry. 2001 Aug 28;40(34):10179-86.

PMID:
11513595
13.

Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.

Huai Q, Wang H, Sun Y, Kim HY, Liu Y, Ke H.

Structure. 2003 Jul;11(7):865-73.

14.

Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).

Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, Strada SJ.

Biochem Pharmacol. 2002 Feb 15;63(4):797-807.

PMID:
11992650
16.

Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.

Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.

Cell Signal. 2001 Mar;13(3):159-67.

PMID:
11282454
18.

Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.

Park H, Young Lee S, Lee DS, Yim M.

Biochem Biophys Res Commun. 2007 Mar 2;354(1):178-83. Epub 2007 Jan 2.

PMID:
17222389
19.

PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.

Murthy KS, Zhou H, Makhlouf GM.

Am J Physiol Cell Physiol. 2002 Mar;282(3):C508-17.

PMID:
11832336
20.

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C.

Br J Pharmacol. 2008 May;154(1):82-92. doi: 10.1038/bjp.2008.56. Epub 2008 Mar 3.

Supplemental Content

Support Center